sábado, 21 de noviembre de 2026
BuscarExplore
Inteligencia rastreable hasta la fuente

Noticias en las que puede confiar

Cada dato rastreado hasta su fuente, y verificado. Explore las empresas, los datos y las conclusiones detrás de las noticias.

Lo que estamos viendo

Conclusiones que nuestra IA extrae de los datos rastreados: léalas como interpretación, cada una respaldada por los datos y las entidades que menciona.

cycle· mixed

Late-2026 Biotech Regulatory Catalyst Wave: Cardiometabolic, Hepatitis Delta and Autoimmune Readouts

A cluster of FDA decision dates and pivotal data readouts runs from mid-November 2026 into Q1 2027. It includes the ivonescimab BLA (PDUFA 14 Nov), the lorundrostat PDUFA (22 Dec), CagriSema REDEFINE 9 results, Maritime-1 completion, and the ECLIPSE 1-3 hepatitis delta readouts. Alongside these, programs such as iadademstat, ianalumab, nipocalimab and plozasiran are moving through mid-to-late-stage development, and one delisting process is under way. Safety remains a risk, as shown by the death in a Chinese gene-editing trial. The AI-policy and outage items in the feed (chip export controls, the California v. OpenAI suit, bank outages) are a separate story and are not part of this narrative.

REDEFINE 9ECLIPSE 1ECLIPSE 2ECLIPSE 3
transformation· mixed

Enterprise Software Q3 2026: AI Agents Drive Monetization While Governance, Security and Finance-Stack Disruption Take Center Stage

Enterprise software vendors reporting Q3 2026 (Qualys, Trimble, Datadog, Planisware, AudioEye) are mostly confirming or raising guidance as AI features, agents and commitment-based offerings gain traction. A parallel storyline is the demand for agent governance and control (ServiceNow Control Tower Alliance, Confluent Streamhouse) and venture interest in AI-driven finance and ERP disruption (Norwest, Dextr, Tiny's Oso Cloud acquisition). Caveats are Trimble's 2027 headwind, a Democratic midterm sweep that CIBC says could favor large cloud and software platforms in a regulation-driven market, and small-cap restructuring such as TEN Holdings.

Qualys ETMPTx TrimbleConfluent Data Streaming PlatformDatadog AI products
transformation· mixed

AI Compute Boom Meets Export Controls and Leadership Turmoil as Capital Pours into Physical AI

Nvidia's blowout Q3 FY2027 results landed alongside a halt to H200 shipments to China. The board chair also said it does not intend to reinstate Jensen Huang as CEO and the company would not discuss the circumstances of his removal. Meanwhile, capital is moving into AI's physical and sensory frontiers: Genesis AI's $500M Series A at a $3.5B valuation, Plural's $1.1B third fund, Osmo's claim of human-level olfactory AI and the Sila–Panasonic anode deal. Consumer AI distribution is expanding (Google's homepage chat sidebar), while autonomy and surveillance face pushback (Waymo off freeways, San Diego dropping Flock cameras) and infrastructure outages add fragility (Microsoft, Apple, NSA).

Harvey JonesAlex WiltschkoGene BerdichevskyRobby Stein
transformation· mixed

Governance Under Pressure: AI Companies Go Public as Boards, Activists and Trade-Secret Risk Reshape Control

Anthropic's Nasdaq debut and the AI Now Institute's review of AI company structures, including Anthropic's Long-Term Benefit Trust and OpenAI's safety committee, put mission-driven governance against shareholder primacy. The same period shows boards acting defensively: Nvidia's board is reported not to intend reinstating Huang, Helen of Troy rejected Empower Brands' $37 bid, and Align and Vivendi are handling executive and balance-sheet transitions. Universal proxy rules are speeding activist settlements, and lawyers warn that employee use of AI tools can leak trade secrets and create new compliance liabilities.

Long-Term Benefit TrustSafety and Security CommitteePublic Good, Private GainShareholder primacy
transformation· mixed

CFO Playbook for a Late-Cycle Squeeze: Cost Discipline, Portfolio Pruning and Regulatory Resets

CFOs across fintech, gaming, biotech, semiconductors and energy services are cutting costs, divesting or exiting businesses, and stretching cash runways. Most are doing it while integrating mergers, leadership changes and regulatory shifts. Examples include High Roller's revenue step-down as it adds prediction markets, Fractyl's roughly 50% cut in cash burn, Infineon's falling idle costs, and the Durbin Amendment and CARLI Guideline in financial services. The tone is disciplined but cautious: guidance is conservative and several firms say they still need more capital.

Adam FelmanLara WeberÉric JobinTridivesh Kidambi
transformation· mixed

Post-ESMO 2026: Oncology Pipelines Converge on PDAC, ADCs and Precision Testing While China's NRDL Rewrites Market Access

ESMO 2026 (late October) was the catalyst for a wave of oncology data. Incyte, Astellas, Merck/Moderna and Innovent presented, with Incyte's combination data in pancreatic cancer (PDAC) the main thread. At the same time, China's 2026 NRDL expansion (seven Innovent products, effective 2027-01-01), US launches such as ZEGFROVY, and diagnostics advances such as Abbott's whole-genome MRD test point to commercialization and market access shaping oncology value. Small-cap biotechs show strain: ADC Therapeutics is cutting its workforce, Akari is guiding to Phase 1 in mid-2027, and one company is pursuing a delisting.

Metastatic pancreatic adenocarcinoma (PDAC)Merck and Moderna melanoma vaccineTABOSUN (Ipilimumab N01 injection)TYVYT (sintilimab injection)
Señales que seguimos
  • Satellite-Terrestrial Network Integration Acceleration

    Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

  • EPKINLY Regulatory-Clinical Success Cascade

    High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

  • Smart Home AI Platform Convergence

    Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products

  • AI Integration Acceleration

    Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances

Hipótesis en estudio
  • NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools

    88% confidence · sin probar
  • Data center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers

    88% confidence · sin probar
  • LLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations

    85% confidence · sin probar
  • AI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance

    85% confidence · sin probar
  • Hyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026

    85% confidence · sin probar
Sources we've traced
all →
Source document

Gaming and Leisure Properties Announces Pricing of $600,000,000 of 6.250% Senior Notes Due 2031

“Gaming and Leisure Properties Announces Pricing of $600,000,000 of 6.250% Senior Notes Due 2031 Gaming and Leisure Properties, Inc. WYOMISSING, Pa., Nov…”

Source document

Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

“Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Scribe Therapeutics Inc…”

Source document

5 Stocks Analysts Are Downgrading Right Now

“5 Stocks Analysts Are Downgrading Right Now Stocks slid again on Tuesday after a hotter-than-expected inflation report fed bets on higher interest rates, and all three major indexes finished lower…”

Source document

5 Best Stocks to Buy After Democrats’ Election Sweep, According to CIBC

“5 Best Stocks to Buy After Democrats’ Election Sweep, According to CIBC CIBC Capital Markets recommended a list of top stock picks after the Democratic sweep of Congress, according to CNBC, citing a potentially tougher regulatory environment for corporate America…”

Source document

Treasury Yields Jump as Inflation Fuels Fed Wagers

“Treasury Yields Jump as Inflation Fuels Fed Wagers A faster-than-estimated increase in inflation spurred a rout in bonds on bets the Federal Reserve will keep lifting rates, but stocks trimmed losses amid a rebound in chipmakers.Phil Neuhart, Director of Market and Economic Research at First Citizens Bank and Ajay Raja…”

Source document

Sen. Warren targets Trump family crypto firms, and miner MARA sold BTC for $1.1 B

“Sen…”

Every fact is traceable to the document it came from: see how we source every claim.

Latest News

View All →
El desplome de los chips tras las elecciones de EE. UU.: Micron duplicó su inversión mientras el sector sufría su peor sesión desde 2020
Analysis

El desplome de los chips tras las elecciones de EE. UU.: Micron duplicó su inversión mientras el sector sufría su peor sesión desde 2020

El 5 de noviembre los semiconductores vivieron su peor sesión desde marzo de 2020, pero las cuentas verificadas de Micron (SEC) y los resultados de Siltronic e Infineon no muestran un negocio en ruinas. Separamos qué está comprobado, qué es secundario y qué falta en el expediente, que no incluye ninguna empresa española o latinoamericana.

Biotecnología con resultados clínicos sólidos y caja récord frente a una caída tecnológica de un billón de dólares: ¿aguantará el capital?
Analysis

Biotecnología con resultados clínicos sólidos y caja récord frente a una caída tecnológica de un billón de dólares: ¿aguantará el capital?

Entre finales de octubre y mediados de noviembre de 2026, la biotecnología avanzó en ensayos y fichajes mientras la tecnología perdía 1 billón de dólares en bolsa. Cruzamos datos verificados de la SEC con comunicados y fuentes medidas por fiabilidad. No hay empresa hispana en el material; lo decimos.

Mercados que no cierran, agentes que compran: lo que está verificado y lo que aún no sabemos sobre la automatización de las finanzas
Analysis

Mercados que no cierran, agentes que compran: lo que está verificado y lo que aún no sabemos sobre la automatización de las finanzas

Nasdaq prevé una jornada de 23 horas, Cboe y Robinhood preparan contratos sobre indicadores de empresas y una startup recauda 35 millones de dólares para identificar agentes de IA. Separamos lo comprobado en documentos y en declaraciones de la SEC de lo que el material no permite afirmar, incluido el impacto en Latinoamérica.

Chips que no llegan a producirse al ritmo de la demanda, industriales que recortan para sostener beneficios: lo que dicen los directores financieros del tercer trimestre de 2026
Analysis

Chips que no llegan a producirse al ritmo de la demanda, industriales que recortan para sostener beneficios: lo que dicen los directores financieros del tercer trimestre de 2026

Lam Research dice que su previsión de ingresos sería mayor sin cuellos de botella de suministro. Dow y Union Pacific protegen márgenes con recortes y control del balance frente a la energía cara. Todas las cifras proceden de llamadas con analistas del 22 de octubre y de datos de la SEC verificados.

Temporada de resultados del tercer trimestre de 2026: del recorte de costes a la banca mexicana, cómo gestionan el dinero los directores financieros
Analysis

Temporada de resultados del tercer trimestre de 2026: del recorte de costes a la banca mexicana, cómo gestionan el dinero los directores financieros

Dow, Union Pacific y el banco mexicano Regional ofrecen tres respuestas distintas a costes de energía altos y demanda desigual. Las cifras de Dow proceden de documentos oficiales ante la SEC y verificados. Las citas de las llamadas con analistas proceden de fuentes con una fiabilidad medida de entre el 52% y el 60%, y lo indicamos.

Fintech apuesta por contratos de resultados para el minorista y por identidad para agentes de IA: lo que dicen los datos verificados
Analysis

Fintech apuesta por contratos de resultados para el minorista y por identidad para agentes de IA: lo que dicen los datos verificados

Robinhood y Cboe preparan contratos binarios sobre resultados de empresas sin comisiones hasta fin de 2026, y Baselayer capta 35 millones de dólares para verificar agentes de IA. Contrastamos ambos movimientos con las cuentas de Robinhood auditadas ante la SEC. Los datos no incluyen nada específico de España ni de Latinoamérica.

Oncología de nueva generación: biespecíficos, vacunas de ARNm e IA atraen capital, pero Summit muestra el coste de llegar al mercado
Analysis

Oncología de nueva generación: biespecíficos, vacunas de ARNm e IA atraen capital, pero Summit muestra el coste de llegar al mercado

Summit Therapeutics, que espera decisión de la FDA sobre ivonescimab el 14 de noviembre, perdió 1.080 millones de dólares en 2025 sin ingresos, según sus informes a la SEC. La Agencia Europea de Medicamentos, que rige para España, recomendó Trodelvy más Keytruda. Las promesas de la IA son, por ahora, previsiones.

Hecho también para máquinas

Cada dato aquí es estructurado y rastreado hasta su fuente, para que los sistemas de IA hereden la verdad de base, no afirmaciones reformuladas. Los mismos datos que una persona lee, un modelo puede consultarlos.

Obtenga vía API →